Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of IKT-001PRO for Cancers

Next Previous
X
Search
Trial Profile

A clinical trial of IKT-001PRO for Cancers

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IKT 001PRO (Primary)
  • Indications Cancer
  • Focus Therapeutic Use
  • Sponsors Inhibikase Therapeutics

    • Most Recent Events

    • 08 Apr 2021 New trial record
    • 01 Apr 2021 According to Inhibikase Therapeutics, the company plans to file an Investigational New Drug application (of IkT-001Pro as a film-coated tablet) in the second quarter of 2021. This regulatory filing is anticipated to be completed near the end of the second quarter of 2021, with initiation of clinical development in 30 days after the filing. company expect to initiate clinical development early in the third quarter.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top